Given the results of KEYNOTE-062 presented at ASCO 2019, how will you utilize immunotherapy in gastric cancer?

KEYNOTE-062 showed deep durable responses are possible with upfront pembro, specifically in the CPS >10 subset, with OS advantage when compared to platinum based chemotherapy. Pembro is currently approved as third line in PD-L1+ patients. In light of this data, would you consider upfront IO for patients with high CPS?

Answer from: Medical Oncologist at Academic Institution

Interpretation of Keynote-062 study results is complicated. The primary endpoint was non-inferiority of pembrolizumab alone versus chemotherapy for first line therapy in patients with CPS>1. This primary endpoint was met, however the PFS curves are quite revealing in that chemotherapy arm do...

Comments

Medical Oncologist at Alliance Cancer Specialists
Your answer is very helpful, but I'd especially li...

Please select the option that best describes you:

Given the results of KEYNOTE-062 presented at ASCO 2019, how will you utilize immunotherapy in gastric cancer?

Related Questions